Drug Type Monoclonal antibody |
Synonyms- |
Target |
Mechanism LILRB4 inhibitors(Leukocyte immunoglobulin-like receptor subfamily B member 4 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hematologic Neoplasms | Preclinical | US | 22 Mar 2024 |